LONDON, UK I 04, 2024 I GSK plc (LSE/NYSE: GSK) and Medicines for Malaria Venture (MMV) announced today that the World Health Organization (WHO) has ...

BERLIN, Germany I 4, 2024 I Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated ...

BIRMINGHAM, AL, USA I 4, 2024 I Treovir, Inc. announced today the opening of a Phase 2 trial testing G207, an oncolytic HSV immunotherapy, in ...

Lilly is granted exclusive worldwide rights to develop a CD28-co-stimulatory therapeutic for a defined cancer target ...

PRINCETON, NJ, USA I SHANGHAI and SUZHOU, China I December 3, 2024 I Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the ...

Rgenta to receive a cash upfront and pre-option milestone payments Rgenta has the potential to receive milestone payments, royalties, and a future equity investment WOBURN, MA, USA I RNA-Targeted ...

Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed ...

In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body ...

BASEL, Switzerland and LONDON, UK and NEW YORK, NY, USA I 03, 2024 I Kinevant Sciences, a clinical-stage biopharmaceutical company developing new ...

Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including ...

TORINO, Italy I 03, 2024 I Resalis Therapeutics today announced the initiation of its first-in-human, Phase 1 study for RES-010, a non-coding ...

PARIS, France I 03, 2024 I Ipsen (Euronext: IPN; ADR: IPSEY) and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for ...